782
Participants
Start Date
December 31, 2000
Study Completion Date
September 30, 2004
Repinotan HCl (BAYX3702)
All patients receive 1.25 mg of repinotan
Placebo
All patients receive 1.25 mg of placebo
Vienna
Bruxelles - Brussel
Gosford
New Lambton Heights
Bornem
Melbourne
Melbourne
Melbourne
Melbourne
Klosterneuburg
Miskolc
Linz
Southport
Hobart
Berlin
Berlin
Stony Brook
Santiago de Compostela
Lahti
Greifswald
Philadelphia
Milan
Baltimore
Nahariya
Como
Pavia
Winston-Salem
Madrid
Decatur
Haifa
Haifa
Minden
Bordeaux
Fort Lauderdale
Tampa
Ocala
Vicenza
Verona
Magdeburg
Reggio Emilia
Essen
Valencia
Münster
Petah Tikva
Zaragoza
Des Moines
Cologne
Tel Litwinsky
Holon
Great Falls
Frankfurt am Main
Aschaffenburg
Tel Aviv
L’Aquila
Kaiserslautern
Heidelberg
Kuopio
Tübingen
Houston
Ashkelon
Freiburg im Breisgau
München
München
Vibo Valentia
Nuremberg
Erlangen
Regensburg
San Jose
Würzburg
Portland
Bad Neustadt an der Saale
Los Angeles
Oceanside
San Diego
Boynton Beach
Honolulu
Robbinsdale
Edison
Ridgewood
New Hyde Park
Chapel Hill
Cleveland
Upland
Beaufort
Chattanooga
Bellevue
Calgary
Edmonton
Lethbridge
North Vancouver
Penticton
Vancouver
Victoria
Winnipeg
Saint John
Halifax
London
Mississauga
Ottawa
Toronto
Chicoutimi
Greenfield Park
Québec
Saskatoon
Helsinki
Mikkeli
Nice
Leipzig
Perugia
Roma
Groningen
Nijmegen
Barcelona
Barcelona
Stockholm
Umeå
Leicester
Glasgow
Dundee
Lead Sponsor
Bayer
INDUSTRY